Optimer Pharmaceuticals Inc (NASDAQ:OPTR)
CAPS Rating:
A biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products.
A biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products.
Recs
FDA approval for Dificid to treat gram positive( C-diff) bacteria, a potentially deadly superbug which causes,clostridium difficile associated diarreah. (CDAD ). This is an alternative drug to Vancomycin which has been the main antibiotic to treat c-diff. In bed with cubist pharmaceuticals.